Child Examinations | North Tonawanda, NY

After Hour Nurse Advice Lines
phone iconPhone: (716) 807-7337
phone iconFax: (716) 807-0848
Receive our Health e-Newsletter


News for Healthier Living

FDA Approves Dual-Action Drug for Patients with Previously Treated Advanced Neuroendocrine Tumors, Backed by Dana-Farber Research

The FDA approval was based on results from the CABINET study, a phase 3 pivotal trial evaluating cabozantinib compared with placebo in two groups of patients with previously treated NETs: advanced pancreatic NETs and advanced extra-pancreatic NETs. The study was led by Jennifer Chan, MD, MPH, clinical director of the gastrointestinal cancer center and director of the program in carcinoid and neuroendocrine tumors at Dana-Farber Cancer Institute.

March 26, 2025


April 1 2025

March 31 2025

March 30 2025

March 29 2025

March 28 2025

March 27 2025

March 26 2025

March 25 2025

March 24 2025

March 23 2025

March 22 2025

March 21 2025

March 20 2025

March 19 2025